AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 in Treatment of Myotonic Dystrophy

AMO Pharma Limited United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/amo-pharma-completes-meeting-with-us-fda-and-outlines-plans-to-advance-clinical-development-of-amo-02-tideglusib-in-treatment-of-myotonic-dystrophy-302133905.html